ArticleBioMed research international2015
Expression of MMP-9 and VEGF in meningiomas and their correlation with peritumoral brain edema.
Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 63 citations in OpenAlex.
- A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma.Journal of neuro-oncology · 2016Trial
- FOXC1 as a molecular predictor of postoperative peritumoral edema resolution in meningiomas.Journal of neuro-oncology · 2026Article
- Peritumoral edema in meningiomas: a review of influencing factors, mechanisms, and management.Frontiers in oncology · 2026Review
- Establishment and evaluation of an automatic multi?sequence MRI segmentation model of primary central nervous system lymphoma based on the nnU?Net deep learning network method.Oncology letters · 2025Article
- Review
- High-intensity Bilateral Hypothalamus on T2-weighted Magnetic Resonance Imaging: A Unique Radiographical Finding of Chordoid Glioma-Report of 3 Cases.NMC case report journal · 2025Article
- The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.Neuro-oncology advances · 2023Article
- Peritumoral edema in meningiomas: pathophysiology, predictors, and principles for treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Review
- HIF 1 α - a promising target for the treatment of meningiomas.Medicine and pharmacy reports · 2023Article
- Article
- Pseudoprogression and peritumoral edema due to intratumoral necrosis after Gamma knife radiosurgery for meningioma.Scientific reports · 2022Article
- Preoperative neutrophil-to-lymphocyte ratio (preNLR) for the assessment of tumor characteristics in lung adenocarcinoma patients with brain metastasis.Translational oncology · 2022Article
- Efficacy of Bevacizumab in High-Grade Meningiomas: A Retrospective Clinical Study.Neuropsychiatric disease and treatment · 2022Article
- Expression of Vascular Endothelial Growth Factor A and Its Type 1 Receptor in Supratentorial Neoplasm.Reports of biochemistry & molecular biology · 2021Article
- Vascular endothelial growth factor concentrations in the cerebrospinal fluid of dogs with neoplastic or inflammatory central nervous system disorders.Journal of veterinary internal medicine · 2021Article
- Regression of Intracranial Meningiomas Following Treatment with Cabozantinib.Current oncology (Toronto, Ont.) · 2021Article
- Influence of VEGF-A, VEGFR-1-3, and neuropilin 1-2 on progression-free: and overall survival in WHO grade II and III meningioma patients.Journal of molecular histology · 2021Article
- Macrophages and microglia: the cerberus of glioblastoma.Acta neuropathologica communications · 2021Review
- Peritumoral edema correlates with mutational burden in meningiomas.Neuroradiology · 2021Article
- A Practical Overview on the Molecular Biology of Meningioma.Current neurology and neuroscience reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas constitute up to 13% of all intracranial tumors. The predictive factors for meningioma have not been unambiguously defined; however some limited data suggest that the expression of matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) may be associated with the presence of peritumoral brain edema (PTBE) and worse clinical outcome. The aim of this study was to analyze the expressions of MMP-9 and VEGF in a group of meningiomas of various grades and to study associations between these two markers and PTBE. The study included patients with supratentorial meningiomas. The patients were divided into low- (G1) and high-grade meningiomas (G2 and G3). PTBE was assessed on MRI. The expressions of VEGF and MMP-9 were determined immunohistochemically. The expression of MMP-9 was observed significantly more often in G3 meningiomas than in lower grade tumors. The presence of stage II or III PTBE was associated with a significant increase in MMP-9 expression. The expression of VEGF did not differ across the PTBE stages. Our findings point to a significant role of MMP-9 and VEGF in the pathogenesis of peritumoral brain edema in low- and high-grade meningiomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.